Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/13/25 | ARS | Annual Report to Security Holders |
|
173 | |
| 03/31/25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
   |
198 |
| 04/23/24 | ARS | Annual report to security holders |
|
160 | |
| 03/21/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
182 |
| 04/21/23 | ARS | Annual report to security holders |
|
156 | |
| 03/16/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
193 |
| 03/17/22 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
281 |
| 03/16/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
179 |
| 03/30/20 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
173 |
